CAS: 57-88-5; (3S,8S,9S,10R,13R,14S,17R)-10,13-Dimethyl-17-((R)-6-Methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-Tetradecahydro-1H-Cyclopenta[a]Phenanthren-3-Ol

上下游产品

CAS号57711-50-9 3-O-叔丁基二甲基甲硅烷基胆固醇 | CAS号33999-75-6 1-((cholesteryl... | CAS号7604-85-5 3β-(Triethylsil... | CAS号25092-65-3 O-allylcholesterol | CAS号6252-45-5 3β-[(Tetrahydro... | CAS号24352-63-4 17-(1,5-dimethy... | CAS号4064-06-6 双丙酮-D-半乳糖 | CAS号1857-80-3 5α,6β-dibrom°Ch... | CAS号2867-93-8 异胆固醇甲基醚 | CAS号70650-16-7 cholesteryl-2-t... | CAS号601-34-3 棕榈酸胆固醇酯 | CAS号35602-69-8 胆甾醇硬脂酸酯 | CAS号566-93-8 4,6-胆固醇二烯-3-酮 | CAS号1232680-81-7 cholesteryl α- ... | CAS号604-35-3 胆固醇乙酸酯 | CAS号601-57-0 4-胆甾烯-3-酮 | CAS号2469-23-0 Cholest-5-ene,3... | CAS号601-54-7 5-胆甾烯-3-酮 | CAS号747-90-0 胆甾-3,5-二烯 | CAS号4351-55-7 甲酸胆固醇酯

(1S,2R,10S,11S,14R,15R)-8-Methoxy-2,15-Dimethyl-14-[(2R)-6-Methylheptan-2-Yl]Pentacyclo[8.7.0.02,7.05,7.011,15]Heptadecane置于硫酸体系中,用 1,4-二氧六环,水 作为反应溶剂,化学反应 3.0H,以97.74%的收率获得产物胆固醇
参考文献:一种以豆甾醇为原料合成胆固醇的方法
标题:一种以豆甾醇为原料合成胆固醇的方法
摘要:一种以豆甾醇为原料合成胆固醇的方法,具体为:(1)豆甾醇与苯磺酰氯反应反应生成磺酸酯,磺酸酯在甲醇中加醋酸钾回流反应得化合物03;(2)化合物03与臭氧发生氧化反应,所得反应液再与锌粉,冰醋酸反应,得化合物04;(3)三苯基膦与1‑卤代‑3‑甲基丁烷反应得3‑甲基丁基三苯基卤化膦;3‑甲基丁基三苯基卤化膦与强碱反应反应生成wittig试剂,Wittig试剂与化合物04发生wittig反应,得化合物05;(4)化合物05在催化剂作用下发生氢化反应,得化合物06;(5)化合物06发生水解反应,得胆固醇01,该方法以豆甾醇为起始原料,廉价易得,工艺简单,消耗原辅料少,收率高,成本低,环保,便于工业化生产.

专利信息

专利号:WO-2024146880-A1
优先权日:2023-01-03
标题:Fluoro-oxysterols positron emission tomography (pet) radiotracers
发明人：POIROT MARC; COURBON FRÉDÉRIC; SAMADI MOHAMMAD; DE MEDINA PHILIPPE; SILVENTE POIROT SANDRINE; BRILLOUET SÉVERINE
权利人:INST NAT SANTE RECH MED; CENTRE NAT RECH SCIENT; UNIV TOULOUSE III – PAUL SABATIER; INST CLAUDIUS REGAUD; CT HOSPITALIER UNIVERSITAIRE TOULOUSE; UNIV DE LORRAINE
摘要:Radiopharmaceuticals-based biomedical imaging plays a growing role in cancer management, including diagnosis, tumor staging and aggressiveness and treatment monitoring. Even though 18Fluoro-2-deoxy glucose and 18Fluoroestradiol are currently used for some types of breast cancer, a need remains to develop other candidate compounds which are useful as radiotracers in a different/ broader range of cancer types. Thus, it is described a family of 18F radiolabeled compounds of formula (I) (wherein one of R2, R4, R5, R6, R7 and R12 is 18F) for use as Positron Emission Tomography imaging agents for the detection of cancers and metastatic sites thereof, as well as for monitoring and predicting the efficacy of a cancer treatment, wherein the cancer is associated to cholesterol-5,6- epoxide hydrolase and/or lip-hydroxy steroid dehydrogenase type (2) overexpression. To overcome the issues linked to the lifetime of the radioisotope 18F and, to ensure an effective synthesis of the 18F radiolabeled compounds of formula (I), a group of novel intermediate compounds in the synthesis thereof is also described.

专利号:WO-2010071772-A2
优先权日:2008-12-15
标题:Synthesis of 3b-amino-5-cholestene and related 3b-halides involving i-steroid and retro-i-steroid rearrangements

专利号:US-8889840-B2
优先权日:2009-10-29
标题 :Vascular leakage inhibitor
发明人：KWON YOUNG-GUEN; SUH YOUNG-GER
权利人:KWON YOUNG-GUEN; SUH YOUNG-GER; UNIV YONSEI IACF
摘要:The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present disclosure inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, enhances the cortical actin ring structure, and improves the stability of the tight junctions (TJs) between vascular cells, thereby inhibiting vascular leakage. The vascular leakage inhibitor of the present disclosure has the activity of not only reducing vascular permeability but also recovering the integrity of damaged blood vessels. Accordingly, the vascular leakage inhibitor of the present disclosure can prevent or treat various diseases caused by vascular leakage. Since the vascular leakage inhibitor of the present disclosure is synthesized from commercially available or easily synthesizable cholesterols, it has remarkably superior feasibility of commercial synthesis.